# Verismo Therapeutics to Present First-in-Human SynKIR™-310 KIR-CAR Clinical Data Showing Robust Antitumor Activity and Favorable Safety Profile in Oral Presentation at 68th ASH Annual Meeting

- Source: PR Newswire M&A
- Published: 2026-11-05T00:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/verismo-therapeutics-to-present-first-in-human-synkir-310-kir-car-clinical-data-showing-robust-antitumor-activity-and-favorable-safety-profile-in-oral-presentation-at-68th-ash-annual-meeting-302929714.html
- Canonical: https://groundlevelnews.com/story/verismo-therapeutics-to-present-first-in-human-synkir-310-kir-car-clin-12dcdf/

Interim clinical data of SynKIR™-310, a CD19-targeted KIR-CAR T therapy, showed no CRS, ICANS, or DLT in the first two dose levels, coupled with robust antitumor activity in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma (B-NHL) Verismo also presenting two preclinical...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._